Bioventus Receives Positive Rating from Craig-Hallum, Analyst Maintains Buy Recommendation

Craig-Hallum analyst Chase Knickerbocker maintains a Buy rating on Bioventus, citing the company's strong performance in the healthcare sector. The analyst consensus on Bioventus is a Strong Buy with an average price target of $11.33. The company has a one-year high of $14.38 and a one-year low of $6.02, with an average volume of 454.1K shares traded per day.

Bioventus Inc. (BVS) is poised to report a decline in its quarterly revenue for the period ending June 30, 2025. Analysts expect the Durham, North Carolina-based company to report a 3.5% decrease in revenue, falling from $151.22 million to $145.863 million [1].

The company's earnings per share (EPS) is projected to be 21 cents, according to the mean estimate from four analysts. The average analyst rating on the shares is a "buy," with a breakdown of three "strong buy" or "buy" ratings, one "hold," and no "sell" or "strong sell" ratings [1].

Despite the expected revenue decrease, Wall Street's median 12-month price target for Bioventus Inc. is $15.00, which is approximately 58.8% above its last closing price of $6.18 [1].

Craig-Hallum analyst Chase Knickerbocker maintains a "Buy" rating on Bioventus, citing the company's strong performance in the healthcare sector. The analyst consensus on Bioventus is a "Strong Buy" with an average price target of $11.33. The company has seen a one-year high of $14.38 and a one-year low of $6.02, with an average daily trading volume of 454.1K shares [2].

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TW1GA:0-bioventus-inc-expected-to-post-earnings-of-21-cents-a-share-earnings-preview/
[2] https://www.craighallum.com/analyst-reports/bioventus-inc/